Improvement in Patient‐Reported Emotional Symptoms and Activity Limitations due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From <scp>ALLEGRO</scp> ‐2b/3
ALLEGRO-2b/3 participants reported greater improvements in ES and AL due to hair loss by Week 48 with the 50-mg ritlecitinib maintenance dose (+/- 200-mg loading dose) versus subtherapeutic 10-mg ritlecitinib.
Authors
- Natasha Atanaskova Mesinkovska (ORCID: https://orcid.org/0000-0002-2705-7002)
- Rodney Sinclair (ORCID: https://orcid.org/0000-0001-6751-1428)
- Ernest H. Law (ORCID: https://orcid.org/0000-0002-6111-8008)
- Costel Chirila (ORCID: https://orcid.org/0000-0002-7495-382X)
- Bintu Sherif (ORCID: https://orcid.org/0000-0002-3251-0078)
- Brett King (ORCID: https://orcid.org/0000-0002-4576-4616)
- Kent A. Hanson (ORCID: https://orcid.org/0000-0002-7201-3324)
- Arash Mostaghimi (ORCID: https://orcid.org/0000-0002-6084-5617)
- Dane Korver (ORCID: https://orcid.org/0009-0007-1147-7532)
Institutions
- Brigham and Women's Hospital (US)
- Pfizer (United States) (US)
- University of California, Irvine (US)
- Yale University (US)
- University of Illinois Chicago (US)
- University of Chicago (US)
- RTI Health Solutions (US)
- Sinclair Dermatology (AU)
Publication Details
- Journal
- International Journal of Dermatology
- Published
- 2025-10-09
- DOI
- https://doi.org/10.1111/ijd.70035
- Citations
- 1
- Primary Topic
- Hair Growth and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.84
Funders
- Pfizer